DOI: 10.23937/2643-4512/1710076

Volume 6 | Issue 2 Open Access



International Archives of **Public Health and Community Medicine**


LETTER TO EDITOR


Definition of Cut-Off Score between COVID-19 Acute Phase and Post-COVID-19 Syndrome: Indispensable Element to Consider in the Use of Instrumental and Clinical Tests

Nicolás Alberto Cely-Aldana, MD¹, Luisa María Benjumea-Gómez, MD², Ronald Antonio Solís-Amin, MD³, Alix Sabec Freire-Duran, MD⁴ and Maria Paz Bolaño-Romero, MS⁵*

¹School of Medicine, Fundación Universitaria Juan N. Corpas, Bogotá, Colombia

⁴School of Medicine, Fundación Universitaria Ciencias de la Salud, Bogotá, Colombia





The COVID-19 pandemic has probably been the worst public health calamity of the 21st century [1]. At the first peak of infection during the early to mid-2020s, much was unknown about the pathophysiology, COVID-19 phenotypes, pharmacologic and supportive management, rehabilitation, and outcomes [2-4]. With precision and celerity, several safe and effective vaccine prototypes were developed to achieve the desired herd immunity and reduce intensive care unit admission and death [5]. Scales have also been designed to measure the impact of COVID-19 on people's quality of life, the performance of normal activities and some others specific to certain conditions [6]. However, there is also talk of post-COVID-19 syndrome and the impact it has on the global burden disease and human quality of life [4,7]. This constitutes a risk period for the development of complications or diseases that did not exist before the acute phase of COVID-19 [4,7]. So, is there really a cutoff score that differentiates the acute phase of COVID-19 from the post-COVID-19 syndrome, which allows to increase the specificity of clinical and diagnostic tools?

Some authors such as Rodríguez-Hernández YA [8]

state that the post-COVID-19 phase is divided into 3 phases: Immediate (3 weeks - 4 weeks), sub-chronic (4 weeks - 12 weeks) and chronic (after 12 weeks) [8]. However, this definition is arbitrary. Particularly, it has been seen that a considerable volume of those who develop complications during the acute phase of COVID-19 partially recover and die during the post-COVID-19 phase from target organ injury. This gives rise to the various phenotypes described, such as post-COVID-19 neurological syndrome, post-COVID 19 tachycardic syndrome, among others. But in reality, it is not known with certainty the relapse caused by SARS-CoV-2 in certain tissues, which is almost always manifested by the same symptoms (fatigue, asthenia, tiredness, neuropsychiatric symptoms, dyspnea, among others) [8].

Currently, when conducting studies and case series/case reports, patients are indiscriminately included and measured in a similar manner, even though the pathophysiologies of the acute phase of COVID-19 and post-COVID-19 syndrome are different. For example, a prospective study in India included patients who



Citation: Aldana NAC, Gómez LMB, Amin RAS, Duran ASF, Romero MPB (2022) Definition of Cut-Off Score between COVID-19 Acute Phase and Post-COVID-19 Syndrome: Indispensable Element to Consider in the Use of Instrumental and Clinical Tests. Int Arch Public Health Community Med 6:076. doi.org/10.23937/2643-4512/1710076

Accepted: April 09, 2022; Published: April 11, 2022

Copyright: © 2022 Aldana NAC, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

²School of Medicine, Universidad Pontificia Bolivariana, Medellín, Colombia

³School of Medicine, Universidad Metropolitana, Barranquilla, Colombia

tested positive for COVID-19 two weeks earlier. 1234 patients were enrolled and followed for up to 3 months, with evidence that 40% persisted with symptoms [9]. However, they found that 18% resolved symptoms at 4 weeks, 12% up to 12 weeks and 10% after 12 weeks. In other words, these authors used as a cut-off score for the onset of the post-COVID phase, from 2 weeks after the onset of symptoms [9]. On the other hand, Crispo, et al. [10] state that The UK's National Institute for Health and Care Excellence defined post-COVID syndrome or Long Covid, as the persistence of symptoms after 12 weeks; and based on this cut-off score, they propose some follow-up strategies [10]. But if one thing is certain, it is that much of the morbidity and mortality occurs long before the age of 3 months.

The above forces us to consider the need to quickly define a cut-off point for the start of the post-COVID-19 syndrome phase, taking into account that many interventions depend on being executed within the appropriate time frame. Tabacof, et al. [11] conducted a cross-sectional study evaluating the impact of post-COVID 19 syndrome on physical function, cognitive function and quality of life [11]. Of 156 participants studied, the median time since the acute phase of COVID-19 was found to be 351 days (range 82 to 457). Of these, 82% reported fatigue, 60% headache and 67% some type of difficulty in performing cognitive processes [11]. Physical exercise, distress and dehydration were the main agents that exacerbate the symptoms. Finally, it was concluded that post-COVID-19 syndrome substantially affects the quality of life of COVID-19 patients [11]. Unfortunately, the fact of taking a population with such a long observation period without strict follow-up allows the presence of a large number of biases; however, it is clear the existence of the post-COVID-19 syndrome and its relevance in the medical field.

It is necessary to carry out well-designed prospective multicenter studies to better understand phenomenon and to propose effective programs to control morbidity and mortality in this risk period. In the meantime, strict follow-up of those with COVID-19 and comorbidities that increase the risk of decompensation should be reinforced. Finally, as long as there are no solid programs of short- and long-term follow-up and rehabilitation of post-COVID-19 syndrome by different specialties at a global level, it is not possible to say with certainty what will be the evolution of the patient and the state of his functional capacity, since the permanent affectation of an organ or system can compromise the total systemic functioning of the individual [12]. For the most part, the current evidence comes from samples of high-income countries, therefore, it is heterogeneous and results cannot always be extrapolated to other population groups with different sociodemographic characteristics. This suggests that much research remains to be done before a cut-off score can be defined, which would allow a robust evidence-based definition to be proposed.

References

- Narayan KMV, Curran JW, Foege WH (2021) The COVID-19 Pandemic as an Opportunity to Ensure a More Successful Future for Science and Public Health. JAMA 325: 525-526.
- Gray AN, Martin-Blais R, Tobin NH, Wang Y, Brooker SL, et al. (2021) Humoral responses to SARS-CoV-2 mRNA vaccines: Role of past infection. PLoS One 16: e0259703.
- Abutaleb A, Nathan S (2021) COVID-19 infectionassociated coagulopathy: Pathophysiology and clinical implications. Interv Neuroradiol 27: 6-12.
- Camargo-Martínez W, Lozada-Martínez I, Escobar-Collazos A, Navarro-Coronado A, Moscote-Salazar L, et al. (2021) Post-COVID 19 neurological syndrome: Implications for sequelae's treatment. J Clin Neurosci 88: 219-225.
- Elliott P, Haw D, Wang H, Eales O, Walters CE, et al. (2021) Exponential growth, high prevalence of SARS-CoV-2, and vaccine effectiveness associated with the Delta variant. Science 374: eabl9551.
- O'Connor RJ, Preston N, Parkin A, Makower S, Ross D, et al. (2021) The COVID-19 Yorkshire Rehabilitation Scale (C19-YRS): Application and psychometric analysis in a post-COVID-19 syndrome cohort. J Med Virol.
- González-Herazo MA, Silva-Muñoz DC, Guevara-Martínez PA, Lozada-Martinez ID (2021) Post-COVID 19 Neurological Syndrome: A fresh challenge in neurological management. Neurol Neurochir Pol 55: 413-414.
- Rodríguez-Hernández YA, Villamizar-Gómez FJ, Mantilla-Pardo JC, Robledo-Arias JS, Rahman S, et al. (2021) Post-COVID 19 neurological syndrome: The need to define a cutoff score between the acute and post-COVID 19 phases. Ann Med Surg (Lond) 71: 102983.
- Naik S, Haldar SN, Soneja M, Mundadan NG, Garg P, et al. (2021) Post COVID-19 sequelae: A prospective observational study from Northern India. Drug Discov Ther 15: 254-260.
- Crispo A, Bimonte S, Porciello G, Forte CA, Cuomo G, et al. (2021) Strategies to evaluate outcomes in long-COVID-19 and post-COVID survivors. Infect Agent Cancer 16: 62.
- Tabacof L, Tosto-Mancuso J, Wood J, Cortes M, Kontorovich A, et al. (2021) Post-acute COVID-19 syndrome negatively impacts physical function, cognitive function, health-related quality of life and participation. Am J Phys Med Rehabil 101: 48-52.
- Lozada-Martínez ID, Díaz-Castillo OJ, Pearson-Arrieta AC, Galeano-Buelvas A, Moscote-Salazar LR (2022) Post-COVID 19 neurological syndrome: A new risk factor that modifies the prognosis of patients with dementia. Alzheimers Dement 18: 542-543.

